What laboratory tests and prophylactic measures are required for a dirty needle‑stick injury, including evaluation of both the exposed individual and the source patient?

Laboratory Requirements for Dirty Needlestick Injury

Immediately test both the source patient and exposed healthcare worker for HIV (antibody or antigen/antibody combination), hepatitis B surface antigen (HBsAg), and hepatitis C antibody (anti-HCV) within 1–2 hours of exposure, using rapid HIV testing when available to expedite post-exposure prophylaxis decisions. 1, 2, 3

Immediate Actions (Within Minutes to 1 Hour)

• Wash the puncture site thoroughly with soap and water without squeezing or applying pressure—caustic agents like bleach should never be applied to the wound. 1, 2

• Flush eyes, nose, or mouth immediately with clean water or saline if blood splashes onto mucous membranes. 2

• Report the incident to your supervisor within 1 hour and document the exact time of injury, device type, depth of penetration, visible blood contamination, fluid type, source patient information, and skin condition (intact vs. compromised). 2, 3

Source Patient Testing (Within 1–2 Hours)

Test the source patient immediately for: 1, 2, 3

• HIV antibody or antigen/antibody combination test (use rapid HIV testing to expedite PEP decisions—repeatedly reactive results are highly suggestive of infection and do not require Western blot confirmation before starting prophylaxis) 1, 2

• Hepatitis B surface antigen (HBsAg) 1, 2, 3

• Hepatitis C antibody (anti-HCV) 1, 2, 3

• If the source is HIV-positive, obtain CD4+ count, viral load, current antiretroviral regimen, and stage of infection to guide PEP selection—but do not delay PEP initiation while waiting for these results. 1

• Never test discarded needles or syringes for viral contamination; results are unreliable and not recommended. 2, 3

Baseline Testing for Exposed Healthcare Worker (Before Starting Prophylaxis)

Obtain the following tests immediately: 1, 2, 3

• HIV antibody or antigen/antibody combination test 2, 3

• Hepatitis B serology: HBsAg, anti-HBs, and anti-HBc 2, 3

• Hepatitis C antibody (anti-HCV) 2, 3

• Alanine aminotransferase (ALT) / liver function tests 2, 3

• Document hepatitis B vaccination history and prior vaccine response (protective anti-HBs ≥10 mIU/mL) 2, 3

• Offer pregnancy testing to women of childbearing age with unknown pregnancy status, as this influences HIV PEP drug selection. 2, 3

HIV Post-Exposure Prophylaxis (Initiate Within 72 Hours)

• Start HIV PEP immediately for percutaneous injuries involving blood or potentially infectious fluids (semen, vaginal secretions, cerebrospinal fluid, synovial fluid, pleural fluid, peritoneal fluid, pericardial fluid, amniotic fluid) from an HIV-positive or unknown-status source—effectiveness drops dramatically after 72 hours. 1, 2

• The preferred regimen is bictegravir/emtricitabine/tenofovir alafenamide (single tablet once daily) for 28 days—completing the full course is essential. 2

• Monitor for drug toxicity every 2 weeks during the 28-day course with complete blood count and renal/hepatic function tests. 2, 3

• Evaluate the worker within 72 hours of starting PEP and continue toxicity monitoring for at least 2 weeks. 2, 3

Hepatitis B Prophylaxis (Initiate Within 24 Hours)

Management depends on the exposed worker's vaccination and immune status: 2, 4

• Unvaccinated or incompletely vaccinated + HBsAg-positive source: Administer hepatitis B immune globulin (HBIG) 0.06 mL/kg intramuscularly as soon as possible (ideally within 24 hours, effective up to 7 days) and begin the hepatitis B vaccine series simultaneously at a separate site. 2, 4

• Previously vaccinated with documented immunity (anti-HBs ≥10 mIU/mL): No treatment required regardless of source status. 2, 4

• Previously vaccinated but non-responder (anti-HBs <10 mIU/mL) + HBsAg-positive source: Give HBIG 0.06 mL/kg immediately and either a vaccine booster dose or a second HBIG dose in 1 month. 2, 4

• Vaccination status unknown + HBsAg-positive source: Test anti-HBs immediately; if negative, give one dose of HBIG and one dose of vaccine at separate sites, then retest anti-HBs at 4–6 months (to avoid detecting passive antibody from HBIG). 2

• HBsAg-negative source: Initiate vaccine series if unvaccinated; HBIG is not required. 4

• Unknown source: Begin vaccine series and consider HBIG if the setting suggests high risk (e.g., AIDS unit, area with prevalent injecting-drug use). 2

Hepatitis C Management

• No post-exposure prophylaxis exists for hepatitis C—early identification through baseline and serial testing is the only strategy. 1, 2, 5

• The average risk of HCV transmission after needlestick from a confirmed positive source is approximately 1.8%. 2

Follow-Up Testing Schedule

HIV Follow-Up 1, 2, 3

• Baseline, 6 weeks, 3 months, and 6 months post-exposure 2, 3

• Perform additional HIV testing immediately if symptoms compatible with acute retroviral syndrome develop (fever, rash, lymphadenopathy, fatigue). 2, 3

• If the source is confirmed HIV-negative with no clinical AIDS signs or recent high-risk behaviors, baseline testing and further follow-up of the worker are generally unnecessary. 2

Hepatitis C Follow-Up 2, 3, 5

• Baseline anti-HCV and ALT at time of exposure 2, 3

• HCV RNA testing at 4–6 weeks post-exposure if earlier diagnosis is desired 2, 3, 5

• Anti-HCV antibody and ALT testing at 4–6 months post-exposure 2, 3, 5

• Confirm any repeatedly reactive anti-HCV enzyme immunoassay with supplemental testing (e.g., recombinant immunoblot assay). 2, 3

Hepatitis B Follow-Up 2, 3

• For workers receiving hepatitis B vaccine after exposure (without HBIG), test anti-HBs 1–2 months after the final vaccine dose. 2, 3

• If HBIG was administered, defer anti-HBs testing until 4–6 months after HBIG to avoid detecting passively transferred antibodies. 2

Precautions During Follow-Up Period

• No modification of patient-care duties is required after exposure to HBV, HCV, or HIV—standard precautions are sufficient. 1, 2

• Use barrier protection during sexual activity and do not donate blood, plasma, organs, tissue, or semen during the follow-up period. 2

• Seek immediate medical evaluation for any acute illness during follow-up (fever, rash, jaundice, fatigue), as this may indicate acute infection. 2, 3

Special Considerations for Unknown or High-Risk Source

• When the source is unknown or cannot be identified, treat the exposure as high-risk and initiate presumptive HIV PEP and HBV prophylaxis (HBIG and vaccine series) without delay. 2

• A blood-filled hollow needle or visibly bloody device indicates higher risk than a standard injection needle. 2

• In high-risk settings (e.g., AIDS unit, areas with prevalent injecting-drug use), consider the exposure high-risk even if the source is unknown. 2

Common Pitfalls to Avoid

• Delaying HIV PEP beyond 72 hours markedly reduces effectiveness—start immediately even before confirming source status for substantial exposures. 1, 2

• Failing to test the source patient when possible eliminates critical information for risk assessment and management decisions. 2, 3

• Inadequate follow-up testing—ensure a system is in place to encourage exposed healthcare workers to return for all scheduled follow-up tests through 6 months. 2, 3

• Squeezing the wound or applying caustic agents provides no benefit and is not recommended. 2

• Testing discarded needles for viral contamination is unreliable and should never be done. 2, 3

• Assuming no risk because the source is unknown is incorrect—management should proceed as if exposure occurred. 2

• Many vaccinated healthcare workers have suboptimal anti-HBs titers (<10 mIU/mL) requiring booster doses—always verify immune status rather than assuming protection. 6